Elastrin Therapeutics

Elastrin Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Greenville, USA, pioneering a first-in-class approach to reverse arterial calcification. Its core technology is a targeted nanoparticle that delivers therapeutic agents directly to damaged elastin, aiming to dissolve pathological calcification non-invasively. The company is targeting a massive global market, starting with over 200 million patients suffering from Peripheral Artery Disease, where calcification is a major driver of morbidity. If successful, Elastrin's therapy could transform the treatment landscape for a wide range of cardiovascular conditions currently lacking effective disease-modifying options.

Targeted nanoparticle platform designed to deliver therapeutic agents specifically to sites of degraded elastin, the protein scaffold where arterial calcification occurs. The platform enables localized dissolution of calcified deposits and can be administered systemically or in combination with medical devices.

The direct competitive landscape for an elastin-targeted calcification reversal therapy is currently sparse, representing a potential first-in-class opportunity. However, indirect competition exists from companies developing therapies for PAD (e.g., pro-angiogenic agents), calcific aortic valve disease, and general cardiovascular risk reduction. Large pharma and device companies active in interventional cardiology are also potential future competitors or partners.